|
|
Volumn 48, Issue 5, 2008, Pages 628-629
|
|
Metabolic changes in protease inhibitor-naive patients treated for 1 year with lopinavir/ritonavir
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
DIDANOSINE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LAMIVUDINE;
LOPINAVIR PLUS RITONAVIR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PROTEINASE INHIBITOR;
STAVUDINE;
TENOFOVIR;
ZIDOVUDINE;
CHOLESTEROL;
LIPID;
LOPINAVIR;
PYRIMIDINONE DERIVATIVE;
RITONAVIR;
ADULT;
CARDIOVASCULAR RISK;
CD4 LYMPHOCYTE COUNT;
CLINICAL EVALUATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DIGESTIVE SYSTEM DISEASE;
DRUG ABUSE;
DRUG WITHDRAWAL;
DYSLIPIDEMIA;
ENZYME INHIBITION;
FAMILY HISTORY;
FEMALE;
FOLLOW UP;
GROUPS BY AGE;
HETEROSEXUALITY;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HOMOSEXUALITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
HYPERTRIGLYCERIDEMIA;
INSULIN RESISTANCE;
ISCHEMIC HEART DISEASE;
LETTER;
LIPOPROTEIN BLOOD LEVEL;
MAJOR CLINICAL STUDY;
MALE;
METABOLIC REGULATION;
METABOLISM;
OUTCOME ASSESSMENT;
PATIENT INFORMATION;
PATIENT SELECTION;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
PROTEINASE INHIBITION;
RISK FACTOR;
SMOKING;
TREATMENT DURATION;
TREATMENT OUTCOME;
VIRUS LOAD;
VIRUS TRANSMISSION;
BLOOD;
CARDIOVASCULAR DISEASE;
DRUG COMBINATION;
GLUCOSE BLOOD LEVEL;
ADULT;
BLOOD GLUCOSE;
CARDIOVASCULAR DISEASES;
CD4 LYMPHOCYTE COUNT;
CHOLESTEROL;
DRUG THERAPY, COMBINATION;
FEMALE;
HIV INFECTIONS;
HIV PROTEASE INHIBITORS;
HUMANS;
INSULIN RESISTANCE;
LIPIDS;
MALE;
PYRIMIDINONES;
RISK FACTORS;
RITONAVIR;
|
|
EID: 50949095526
PISSN: 15254135
EISSN: None
Source Type: Journal
DOI: 10.1097/QAI.0b013e31816d9cf8 Document Type: Letter |
|
Times cited : (3)
|
|
References (5)
|
